1.
J Pediatr Hematol Oncol
; 24(9): 777-8, 2002 Dec.
Artigo
em Inglês
| MEDLINE
| ID: mdl-12468925
RESUMO
This report describes the sustained response of an Iranian girl with homozygous beta(0) thalassemia (IVS-II-1G-->A) to hydroxyurea (HU) and recombinant erythropoietin (rEPO). Since the start of this regimen 7 years ago, she has been transfusion-independent and her hemoglobin is maintained between 9.5-11.0 gm/dL. She is maintaining consistent growth around the 10th percentile for age and enjoys a good quality of life. She has not had any therapy-related adverse effects. This experience suggests that therapy with HU and rEPO may be useful long-term in some patients with beta thalassemia.
Assuntos
Eritropoetina/uso terapêutico , Hidroxiureia/uso terapêutico , Talassemia beta/tratamento farmacológico , Antidrepanocíticos/uso terapêutico , Criança , Feminino , Hepatomegalia/etiologia , Humanos , Proteínas Recombinantes , Esplenomegalia/etiologia , Transplante de Células-Tronco , Talassemia beta/sangue
2.
J Pediatr
; 140(5): 608-13, 2002 May.
Artigo
em Inglês
| MEDLINE
| ID: mdl-12032530